Our Team

We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines.

Dr. Klaus Breiner

Managing Partner

Venture capital investor since 2001, joined Bellevue in 2004. Co-founder and former Executive Chairman of Vaximm, a Swiss-German immuno-oncology company. Prior to Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Cadence, Glycart, Intercell, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.

Dr. Dominik Escher

Managing Partner

Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 mn in 2009. Subsequently until 2016 Vice President of Alcon R&D. Member of the Global Ophthalmology Leadership and Global Biologics Leadership of Novartis Institutes of Biomedical Research. Since 2002 on the Board of the Swiss Biotech Association.

Dr. Martin Münchbach

Managing Partner

Venture capital investor since 1999, investing in life science companies across all stages and types. Joined Bellevue Group in 2004. Martin’s investments and board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer, Axovan and Glycart. PhD Protein Chemist & Biochemist.

Dr. Anja Harmeier


Experienced Scientist, Entrepreneur and Drug Developer in Neuroscience and various Rare Diseases. Over the last 4 years Anja was an Investment Director at the Roche Venture Fund sourcing, leading and managing global investments in various areas and stages like Black Diamond, Vivet, Entrada and NMD. PhD Neuroscientist & Biochemist, MBA

Dr. Ximing Ding


Analyst at Pureos Bioventures since 2018. Prior to joining Pureos Bioventures, Post-doc and PhD at European Molecular Biology Laboratory and consulting internship at IMS Health (now IQVIA). PhD Molecular Biologist.

Dr. Alexander Breidenbach

Entrepreneur in Residence

Former business development manager at F. Hoffmann-La Roche AG. Pharmacologist with more than 20 years experience in R&D and partnering in pharma, 16 years at global level. Particular expertise in neuroscience, ophthalmology, and rare diseases. Ph.D. Veterinary Medicine and Executive MBA from ESSEC Paris & Mannheim Business School.

Dr. Michael Motz

Entrepreneur in Residence

Former CEO Algobate AG, before that in partnering at F. Hoffmann-La Roche AG, Corporate Development at ALTANA Pharma AG and Strategic Planning at Sandoz International, R&D at LION Bioscience AG. 20 years in industry and last 10 years in CEO and business development roles. Particular expertise in inflammation, autoimmune and fibrotic diseases. PhD in Biochemistry at MPI Leipzig.

Dr. Omar Khwaja

Advisory Board

Chief Medical Officer and Head of Research and Development of Voyager Therapeutics. Previously Global Head of Neuroscience Translational Medicine and Rare Diseases at Roche, and before that Chief Resident at Harvard Medical School. MD Ph.D. from the University of Cambridge, UK.

Prof. Dr. Roger Nitsch

Advisory Board

CEO and President of Neurimmune; key opinion leader in neurodegenerative diseases; developer of aducanumab (Alzheimer’s disease) now in partnership with Biogen. Part-time professor at the Institute for Regenerative Medicine, University of Zurich.

Prof. Dr. Bernd Seizinger

Advisory Board

Former President & CEO of GPC Biotech, NASDAQ listed oncology company. He built the company from a pre-clinical stage to a phase 3 clinical oncology company. Prior to that VP Oncology drug discovery at Bristol-Myers Squibb. Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.

Dr. Mathieu Simon

Advisory Board

Chairman at Idorsia (SWX: IDIA.SW), former EVP, COO and board director of Cellectis (NASDAQ: CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.

Dallas Webb

Advisory Board

Portfolio Manager at BB Biotech AG in New York since 2006, prior healthcare equity analyst positions with Stanford, Sterling, and Adam Harkness & Hill. Dallas holds an MBA and a BS in Microbiology.

Ben Morgan